Stergiou Angelos M. 4
4 · SELLAS Life Sciences Group, Inc. · Filed Feb 1, 2022
Insider Transaction Report
Form 4
Stergiou Angelos M.
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2022-01-31+165,000→ 165,000 totalExercise: $5.34Exp: 2032-01-31→ Common Stock (165,000 underlying) - Award
Common Stock
2022-01-31+44,000→ 165,167 total
Footnotes (2)
- [F1]The Reporting Person received an award of 44,000 restricted stock units on January 31, 2022, which shall vest as follows: (i) 25% on December 1, 2022 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
- [F2]One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 31, 2022 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.